Riskpilot← Back to searchSign inGet full accessRxElites AB
ABActiveOrg 5595217034Krokåkersgatan 34Retail sale of pharmaceutical products · NACE 4773Est. 20251-4 employees
Revenue 2025
SEK 840K
EBITDA margin
54.9%
Equity ratio
69.1%
Financial strength
Net profit 2025
SEK 366K
| Revenue | SEK 840K | — |
| EBITDA | SEK 461K | — |
| Net profit | SEK 366K | — |
| Total assets | SEK 565K | — |
| Equity | SEK 391K | — |
| Employees | — | — |
Legal name
RxElites AB
Org number
5595217034
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
3 mars 2025
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva konsultverksamhet inom Life science och utbildning samt därmed förenlig verksamhet. Bolaget får i övrigt ägna sig åt kapitalplacering i värdepapper och fast egendom samt därmed förenlig verksamhet
Address
Krokåkersgatan 34
Email
rxelitesab@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2025 |
|---|---|
| Revenue | 840 |
| Staff expenses | −317 |
| EBITDA | 461 |
| Depreciation & amort. | — |
| EBIT | 461 |
| Net financials | −0 |
| Profit before tax | 461 |
| Tax | −95 |
| Net profit | 366 |
| Item | 2025 |
|---|---|
| Total assets | 565 |
| Equity | 391 |
| Long-term debt | 3 |
| Short-term debt | 171 |
| Total debt | 175 |
EBITDA margin
54.9%
This company
15.8%
Market median
+247% vs market
20252025
Equity ratio
69.1%
This company
38.2%
Market median
+81% vs market
20252025
Return on equity
93.6%
This company
18.4%
Market median
+409% vs market
20252025
Net profit margin
43.5%
This company
8.1%
Market median
+437% vs market
20252025
Asset turnover
1.49×
This company
1.12×
Market median
+33% vs market
20252025
Debt / equity
0.45×
This company
0.62×
Market median
+27% vs market
20252025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-03-03 – 2025-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2026 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Deputy Board Member | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of RxElites AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Philip Anders Franzén | Deputy Board Member | 0 companies |
| Lubna Mohamed Mehdawi Mehdawi | Deputy Board Member | 0 companies |
| Sama Haitham Lamin | Deputy Board Member | 0 companies |
| Ali Lateef Hulo | Deputy Board Member | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Haitham Saad Lamin | Board of Directors | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |